[{"id":"5a3f91fc-1205-487d-92df-2b35d3f75bbe","acronym":"SHIELD-1","url":"https://clinicaltrials.gov/study/NCT03993873","created_at":"2021-01-18T19:38:12.132Z","updated_at":"2024-07-02T16:35:28.600Z","phase":"Phase 1/2","brief_title":"Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET","source_id_and_acronym":"NCT03993873 - SHIELD-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET fusion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elzovantinib (TPX-0022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 09/21/2019","start_date":" 09/21/2019","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2023-11-20"}]